文献速递中枢神经肿瘤放疗胸部肿瘤放疗

EGFR或ALK突变非小细胞肺癌脑转移的多学科治疗系统综述与荟萃分析

Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches.
PubMed 文献 · Radiother Oncol · 2019-12-05

结果显示ALK和EGFR突变患者中位OS分别为48.5个月和20.9个月,显著优于野生型的9.9个月;TKI联合放疗较TKI单药中位PFS有升高趋势但无统计学差异,且未发现联合治疗较放疗单药带来PFS或OS获益。

要点

  • ALK突变脑转移患者中位OS达48.5个月,EGFR突变20.9个月,均显著优于野生型9.9个月。
  • TKI联合放疗较TKI单药中位PFS为18.6 vs 13.6个月,P=0.06,未达统计学差异。
  • TKI联合放疗较放疗单药未显示PFS或OS获益,WBRT或SRS亚组分析亦无差异。

核心结论

  • EGFR或ALK突变NSCLC脑转移患者OS显著优于野生型患者。
  • 在放疗基础上加用TKI未发现PFS或OS获益。

研究设计与样本

  • 干预为初始TKI单药(可联合挽救性放疗)、放疗单药(WBRT或SRS)或TKI联合放疗;对照分别为野生型NSCLC和TKI单药。
  • 结局为总生存(OS)和颅内无进展生存(PFS)。

主要发现

  • ALK突变患者中位OS为48.5个月(p<0.0001),EGFR突变患者为20.9个月(p=0.0006),野生型为9.9个月。
  • TKI联合放疗、放疗单药与TKI单药的中位OS分别为28.3、32.2和23.9个月,组间无显著差异(p=0.22;p=0.2)。
  • TKI联合放疗较TKI单药中位PFS为18.6 vs 13.6个月(p=0.06),TKI联合放疗与放疗单药比较为18.6 vs 16.9个月(p=0.72)。
  • WBRT联合TKI与WBRT单药中位PFS为23.2 vs 24个月(p=0.72),SRS联合TKI与SRS单药为16.7 vs 13.6个月(p=0.56)。

关键数值与推荐

  • EGFR或ALK突变NSCLC脑转移患者中位OS:ALK 48.5个月,EGFR 20.9个月,野生型9.9个月。
  • TKI联合放疗、放疗单药、TKI单药中位OS分别为28.3、32.2、23.9个月。
  • TKI联合放疗与TKI单药中位PFS分别为18.6和13.6个月(p=0.06)。
  • WBRT联合TKI与WBRT单药中位PFS分别为23.2和24个月(p=0.72)。
  • SRS联合TKI与SRS单药中位PFS分别为16.7和13.6个月(p=0.56)。

临床怎么用

  • EGFR或ALK突变NSCLC脑转移患者预后显著优于野生型,治疗决策中应考虑突变状态。
  • 现有证据未显示在放疗基础上加用TKI可改善PFS或OS,联合治疗的选择需结合临床实际个体化判断。

局限性

  • 原文未报告纳入研究的具体异质性评估、发表偏倚分析及证据质量分级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To analyze outcomes of non-small cell lung cancer (NSCLC) patients with brain metastases harboring EGFR or ALK mutations and examine for differences between tyrosine kinase inhibitors (TKIs) alone, radiotherapy (RT) alone (either whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS)), or combined TKIs and RT. MATERIALS AND METHODS: Thirty studies were identified. PATIENTS: with brain metastases from NSCLC. INTERVENTION: initial TKIs alone with optional salvage RT, RT alone, or TKIs and RT. CONTROL: wild-type NSCLC and TKIs alone for mutational and treatment analysis, respectively. OUTCOMES: overall survival (OS) and intracranial progression-free survival (PFS). SETTING: studies with mutation information. RESULTS: A total of 2649 patients were included. Patients with ALK and EGFR mutations had significantly higher median OS (48.5 months, p < 0.0001; and 20.9 months; p = 0.0006, respectively) compared to wild-type patients (9.9 months). Similar median OS was noted between TKIs and RT (28.3 months), RT alone (32.2 months; p = 0.22), or TKIs alone (23.9 months; p = 0.2). Patients treated with TKIs and RT had higher median PFS (18.6 months; p = 0.06) compared to TKIs alone (13.6 months) with no difference between TKIs and RT vs. RT alone (16.9 months; p = 0.72). No PFS difference was found between WBRT and TKI (23.2 months; p = 0.72) vs. WBRT alone (24 months) or SRS and TKI (16.7 months; p = 0.56) vs. SRS alone (13.6 months). CONCLUSION: NSCLC patients with brain metastases harboring EGFR or ALK mutations have superior OS compared to wild-type patients. No PFS or OS benefit was found with the addition of TKIs to RT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Singh R, Lehrer EJ, Ko S, et al. Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches. Radiother Oncol. 2019. PMID: 31812932. doi:10.1016/j.radonc.2019.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。